Herzinsuffizienz und SARS-CoV-2

Zusammenfassung

Die kardiale Beteiligung bei an COVID-19 Erkrankten ist wichtig und prognostisch bedeutend und wurde in vielen Studien belegt. Besonders für kardial vorerkrankte Patienten ergeben sich daraus wichtige Erkenntnisse. Im Sinne der Herzinsuffizienz trifft das ebenfalls zu. Dabei ist klar, dass eine bestehende Herzinsuffizienz wichtig für die Prognose der COVID-19-Erkrankung ist und diese wesentlich verschlechtert. Die Medikation für die chronische Herzinsuffizienz mit reduzierter EF sollte dringend beibehalten werden. Eine neuauftretende Herzinsuffizienz durch die COVID-19-Erkrankung ist selten. Das wichtige Thema der Symptome nach einer COVID-19-Erkrankung inkludiert Beschwerden, die einer Herzinsuffizienz ähnlich sind. Ob diese allerdings auch mit einer Herzinsuffizienz zusammenhängen, muss noch geklärt werden.

Abstract

Many patients suffering from COVID-19 have a cardiac manifestation of the disease. This limits prognosis as shown in many studies. Heart failure is also an important comorbidity reducing survival significantly. Medical therapy in chronic heart failure should be continued as it does not aggravate the course of COVID-19. Newly diagnosed heart failure after COVID-19 is rare and causality difficult to establish. This is also true for heart failure like symptoms in Long-COVID-19.

Schlüsselwörter

Herzinsuffizienz - SARS-CoV-2 / COVID-19 - kardiale Beteiligung

Keywords

SARS-CoV-2 / COVID-19 - cardiac manifestation - heart failure

• Literatur

• 1 König S, Hohenstein S, Meier-Hellmann A. et al. In-hospital care in acute heart failure during the COVID-19 pandemic: insights from the German-wide Helios hospital network. Eur J Heart Fail 2020; 22: 2190-2201
• 2 Bhatt AS, Jering KS, Vaduganathan M. et al. Clinical Outcomes in Patients With Heart Failure Hospitalized With COVID-19. JACC Heart Fail 2021; 9: 65-73
• 3 Tomasoni D, Inciardi RM, Lombardi CM. et al. Impact of heart failure on the clinical course and outcomes of patients hospitalized for COVID-19. Results of the Cardio-COVID-Italy multicentre study. Eur J Heart Fail 2020; 22: 2238-2247
• 4 Birati EY, Najjar SS, Tedford RJ. et al. Characteristics and Outcomes of COVID-19 in Patients on Left Ventricular Assist Device Support. Circ Heart Fail 2021; 14: e007957
• 5 Lopes RD, Macedo AVS, de Barros E Silva PGM. et al. Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial. JAMA 2021; 325: 254-264
• 6 Cohen JB, Hanff TC, William P. et al. Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial. Lancet Respir Med 2021; 9: 275-284
• 7 Mitjà O, Corbacho-Monné M, Ubals M. et al. A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19. N Engl J Med 2021; 384: 417-427
• 8 Lindner D, Fitzek A, Bräuninger H. et al. Association of Cardiac Infection With SARS-CoV-2 in Confirmed COVID-19 Autopsy Cases. JAMA Cardiol 2020; 5: 1281-1285
• 9 Kawakami R, Sakamoto A, Kawai K. et al. Pathological Evidence for SARS-CoV-2 as a Cause of Myocarditis: JACC Review Topic of the Week. J Am Coll Cardiol 2021; 77: 314-325
• 10 Puntmann VO, Carerj ML, Wieters I. et al. Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19). JAMA Cardiol 2020; 5: 1265-1273
• 11 Kotecha T, Knight DS, Razvi Y. et al. Patterns of myocardial injury in recovered troponin-positive COVID-19 patients assessed by cardiovascular magnetic resonance. Eur Heart J 2021;
• 12 Alvarez-Garcia J, Jaladanki S, Rivas-Lasarte M. et al. New Heart Failure Diagnoses Among Patients Hospitalized for COVID-19. J Am Coll Cardiol 2021; 77: 2260-2262
• 13 Evans RA, McAuley H, Harrison EM. et al. Physical, cognitive and mental health impacts of COVID-19 following hospitalisation – a multi-centre prospective cohort study. medRxiv 2021;
• 14 Tazare J, Walker AJ, Tomlinson L. et al. Rates of serious clinical outcomes in survivors of hospitalisation with COVID-19: a descriptive cohort study within the OpenSAFELY platform. medRxiv 2021;